|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HERC5 |
Gene summary for HERC5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HERC5 | Gene ID | 51191 |
| Gene name | HECT and RLD domain containing E3 ubiquitin protein ligase 5 | |
| Gene Alias | CEB1 | |
| Cytomap | 4q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | B4DXV3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51191 | HERC5 | LZE20T | Human | Esophagus | ESCC | 1.64e-02 | 1.67e-01 | 0.0662 |
| 51191 | HERC5 | LZE24T | Human | Esophagus | ESCC | 2.04e-06 | 2.06e-01 | 0.0596 |
| 51191 | HERC5 | P2T-E | Human | Esophagus | ESCC | 3.35e-40 | 8.00e-01 | 0.1177 |
| 51191 | HERC5 | P5T-E | Human | Esophagus | ESCC | 2.03e-09 | 1.68e-01 | 0.1327 |
| 51191 | HERC5 | P8T-E | Human | Esophagus | ESCC | 7.90e-03 | 9.30e-02 | 0.0889 |
| 51191 | HERC5 | P11T-E | Human | Esophagus | ESCC | 9.20e-14 | 5.19e-01 | 0.1426 |
| 51191 | HERC5 | P15T-E | Human | Esophagus | ESCC | 4.23e-06 | 2.05e-01 | 0.1149 |
| 51191 | HERC5 | P16T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.17e-01 | 0.1153 |
| 51191 | HERC5 | P17T-E | Human | Esophagus | ESCC | 3.80e-02 | 2.49e-01 | 0.1278 |
| 51191 | HERC5 | P20T-E | Human | Esophagus | ESCC | 2.70e-03 | 3.33e-01 | 0.1124 |
| 51191 | HERC5 | P21T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.80e-01 | 0.1617 |
| 51191 | HERC5 | P22T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.04e-01 | 0.1236 |
| 51191 | HERC5 | P23T-E | Human | Esophagus | ESCC | 2.10e-09 | 3.30e-01 | 0.108 |
| 51191 | HERC5 | P24T-E | Human | Esophagus | ESCC | 1.88e-11 | 3.15e-01 | 0.1287 |
| 51191 | HERC5 | P26T-E | Human | Esophagus | ESCC | 5.30e-21 | 4.48e-01 | 0.1276 |
| 51191 | HERC5 | P27T-E | Human | Esophagus | ESCC | 2.03e-09 | 2.16e-01 | 0.1055 |
| 51191 | HERC5 | P28T-E | Human | Esophagus | ESCC | 3.60e-13 | 2.48e-01 | 0.1149 |
| 51191 | HERC5 | P31T-E | Human | Esophagus | ESCC | 1.43e-42 | 8.55e-01 | 0.1251 |
| 51191 | HERC5 | P36T-E | Human | Esophagus | ESCC | 4.88e-07 | 3.09e-01 | 0.1187 |
| 51191 | HERC5 | P37T-E | Human | Esophagus | ESCC | 7.56e-11 | 1.84e-01 | 0.1371 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000961518 | Esophagus | ESCC | response to virus | 238/8552 | 367/18723 | 6.65e-14 | 3.32e-12 | 238 |
| GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
| GO:00516075 | Esophagus | ESCC | defense response to virus | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:01405465 | Esophagus | ESCC | defense response to symbiont | 171/8552 | 265/18723 | 3.91e-10 | 1.05e-08 | 171 |
| GO:19040294 | Esophagus | ESCC | regulation of cyclin-dependent protein kinase activity | 69/8552 | 98/18723 | 6.04e-07 | 7.91e-06 | 69 |
| GO:00000794 | Esophagus | ESCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 66/8552 | 94/18723 | 1.24e-06 | 1.53e-05 | 66 |
| GO:00028318 | Esophagus | ESCC | regulation of response to biotic stimulus | 191/8552 | 327/18723 | 2.12e-06 | 2.45e-05 | 191 |
| GO:00506884 | Esophagus | ESCC | regulation of defense response to virus | 45/8552 | 69/18723 | 8.26e-04 | 4.27e-03 | 45 |
| GO:000961511 | Liver | HCC | response to virus | 210/7958 | 367/18723 | 7.32e-09 | 1.86e-07 | 210 |
| GO:00516071 | Liver | HCC | defense response to virus | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:01405461 | Liver | HCC | defense response to symbiont | 151/7958 | 265/18723 | 1.27e-06 | 1.85e-05 | 151 |
| GO:007190021 | Liver | HCC | regulation of protein serine/threonine kinase activity | 189/7958 | 359/18723 | 5.97e-05 | 5.47e-04 | 189 |
| GO:00028312 | Liver | HCC | regulation of response to biotic stimulus | 173/7958 | 327/18723 | 8.55e-05 | 7.48e-04 | 173 |
| GO:0000079 | Liver | HCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 55/7958 | 94/18723 | 1.25e-03 | 6.91e-03 | 55 |
| GO:1904029 | Liver | HCC | regulation of cyclin-dependent protein kinase activity | 57/7958 | 98/18723 | 1.26e-03 | 6.92e-03 | 57 |
| GO:0050688 | Liver | HCC | regulation of defense response to virus | 41/7958 | 69/18723 | 3.38e-03 | 1.54e-02 | 41 |
| GO:000961515 | Oral cavity | OSCC | response to virus | 215/7305 | 367/18723 | 1.63e-14 | 9.41e-13 | 215 |
| GO:007190010 | Oral cavity | OSCC | regulation of protein serine/threonine kinase activity | 201/7305 | 359/18723 | 3.90e-11 | 1.27e-09 | 201 |
| GO:00516074 | Oral cavity | OSCC | defense response to virus | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| GO:01405464 | Oral cavity | OSCC | defense response to symbiont | 154/7305 | 265/18723 | 1.96e-10 | 5.63e-09 | 154 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HERC5 | SNV | Missense_Mutation | rs145240865 | c.1219N>T | p.Arg407Trp | p.R407W | Q9UII4 | protein_coding | deleterious(0) | benign(0.251) | TCGA-A8-A06U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HERC5 | SNV | Missense_Mutation | c.2113N>C | p.Asp705His | p.D705H | Q9UII4 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| HERC5 | SNV | Missense_Mutation | rs760663348 | c.3017N>C | p.Met1006Thr | p.M1006T | Q9UII4 | protein_coding | deleterious(0) | benign(0.355) | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| HERC5 | SNV | Missense_Mutation | c.1042N>A | p.Glu348Lys | p.E348K | Q9UII4 | protein_coding | tolerated(0.14) | benign(0.017) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| HERC5 | SNV | Missense_Mutation | novel | c.1497N>T | p.Met499Ile | p.M499I | Q9UII4 | protein_coding | deleterious(0) | possibly_damaging(0.542) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| HERC5 | insertion | Nonsense_Mutation | novel | c.836_837insCAAAGGTACAATATTGTGATATTATACTAGGT | p.Thr280LysfsTer6 | p.T280Kfs*6 | Q9UII4 | protein_coding | TCGA-A8-A079-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| HERC5 | deletion | Frame_Shift_Del | novel | c.1335delN | p.Asn446IlefsTer10 | p.N446Ifs*10 | Q9UII4 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| HERC5 | SNV | Missense_Mutation | rs751293985 | c.3043N>A | p.Glu1015Lys | p.E1015K | Q9UII4 | protein_coding | deleterious(0.02) | benign(0.065) | TCGA-C5-A7CL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | PD |
| HERC5 | SNV | Missense_Mutation | rs766394501 | c.1571N>T | p.Ser524Leu | p.S524L | Q9UII4 | protein_coding | tolerated(0.24) | benign(0.003) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| HERC5 | SNV | Missense_Mutation | novel | c.1887C>G | p.Phe629Leu | p.F629L | Q9UII4 | protein_coding | tolerated(0.09) | benign(0.052) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |